News
-
Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial
2/19/2013
Concert Pharmaceuticals, Inc. announced today that it has completed enrollment of patients in a Phase 2 clinical trial evaluating CTP-499 for the treatment of diabetic kidney disease. CTP-499 is intended to slow progression of kidney damage in diabetic kidney disease and be additive to the current standard of care, which is treatment with an angiotensin converting enzyme inhibitor (ACEi) and/or an angiotensin receptor blocker (ARB). Concert expects to report top-line results from the Phase 2 study during the second-half of 2013.
-
Ablynx's Anti-IL-6R Nanobody, ALX-0061, Shows Excellent 24 Week Safety And Efficacy Results In A Phase II Clinical Trial In Rheumatoid Arthritis
2/13/2013
Ablynx (EURONEXT BRUSSELS: ABLX) today announced efficacy and safety data for its anti-IL-6R Nanobody, ALX-0061, at the 24 week final analysis of the Phase II part of a combined Phase I/II study in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.
-
FDA Agreement On Mesoblast's Use Of Singapore Manufacturing Facility For Clinical Trial Production Of Proprietary Mesenchymal Precursor Cells
2/12/2013
Mesoblast Limited (ASX:MSB) (OTC ADR:MBLTY) today announced that United States Food and Drug Administration (FDA) is in agreement for Mesoblast to supply its proprietary Mesenchymal Precursor Cells (MPCs) for clinical trials in the United States under Investigational New Drug (IND) protocols, from Lonza's contract manufacturing facility in Singapore, in addition to its United States facility.
-
Portola And Lee's Pharmaceutical Enter Into Agreement To Expand Phase 3 APEX Study Of Betrixaban Into China
1/29/2013
Portola Pharmaceuticals, Inc. and Lee's Pharmaceutical (HK) Ltd. (
HKSE : 0950) today announced an agreement to jointly expand the Phase 3 APEX study of betrixaban into China, with an option for Lee's to negotiate for the commercial rights to the drug in China. -
Cell Therapeutics Begins Enrollment In Phase 3 PERSIST-1 Trial Of Pacritinib For The Treatment Of Myelofibrosis
1/9/2013
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis.
-
Savant HWP Announces NIDA Funding For Pre-Clinical Development Of 18-MC As Potential Treatment For Addiction, Obesity
1/3/2013
Savant HWP, Inc. today announced the receipt of a three-year grant to support the development of 18-MC (18-methoxycoronaridine) as a potential orally active treatment for drug addiction, obesity and other forms of compulsive behavior.
-
FDA Approves GlaxoSmithKline's Four-Strain Seasonal Influenza Vaccine For Use In The U.S.
12/17/2012
GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has approved FLUARIX® QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.
-
Astrazeneca Announces Top-Line Results Of OSKIRA-4 Phase IIb Study Of Fostamatinib As A Monotherapy For Rheumatoid Arthritis
12/13/2012
AstraZeneca recently announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).
-
Theravance Announces Initiation Of Phase 2b Study With Its LAMA Candidate, TD-4208, For The Treatment Of COPD
12/11/2012
Theravance, Inc. (NASDAQ: THRX) announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD.
-
Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, In Patients With Epilepsy
12/3/2012
Upsher-Smith Laboratories, Inc., (Upsher-Smith) announced that Phase I data for USL261 (intranasal midazolam) in patients with epilepsy were presented at the American Epilepsy Society Annual Meeting in San Diego, CA.